These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22105611)

  • 21. An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
    Miki M; Kawabe K; Igarashi H; Abe T; Ohishi Y; Hashimoto R; Karashima T; Yamasaki I; Inoue K; Ito T; Ogawa Y
    Intern Med; 2018 Jul; 57(14):2007-2011. PubMed ID: 29491307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
    Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
    J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
    Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL
    Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice.
    Karashima T; Inoue K; Fukata S; Iiyama T; Kurabayashi A; Kawada C; Shuin T
    Int J Oncol; 2007 Apr; 30(4):937-45. PubMed ID: 17332933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
    Molina AM; Feldman DR; Ginsberg MS; Kroog G; Tickoo SK; Jia X; Georges M; Patil S; Baum MS; Reuter VE; Motzer RJ
    Invest New Drugs; 2012 Feb; 30(1):335-40. PubMed ID: 20711632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: treatment with interleukin-2.
    Williams C; Walther M
    ScientificWorldJournal; 2005 Jan; 5():9-10. PubMed ID: 15674444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
    Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
    Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
    Park S; Lee J; Park SH; Park JO; Kang WK; Park YS; Cho JH; Lim HY
    Chemotherapy; 2010; 56(6):485-91. PubMed ID: 21099221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
    Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
    Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2015 May; 94(2):238-50. PubMed ID: 25638704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
    Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
    Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease.
    Tsimafeyeu I; Demidov L
    J Cancer Res Ther; 2010; 6(4):575-7. PubMed ID: 21358107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
    Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
    Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.
    Sizdahkhani S; Feldman MJ; Piazza MG; Ksendzovsky A; Edwards NA; Ray-Chaudhury A; Maric D; Merrill MJ; Pacak K; Zhuang Z; Chittiboina P
    Sci Rep; 2017 Jan; 7():40822. PubMed ID: 28094316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
    Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Hariharan S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Nieto A; Yuan J; Bukowski R
    Lancet Oncol; 2009 Aug; 10(8):757-63. PubMed ID: 19615940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.